Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictorof AIDS‐Related Lymphoma | Zendy

Alexander Zoufaly | Zendy; HansJürgen Stellbrink | Zendy; Matthias an der Heiden | Zendy; Christian Kollan | Zendy; Christian Hoffmann | Zendy; Jan van Lunzen | Zendy; Osamah Hamouda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cumulative HIV Viremia during Highly Active Antiretroviral Therapy Is a Strong Predictorof AIDS‐Related Lymphoma

Author(s) -

Alexander Zoufaly,

HansJürgen Stellbrink,

Matthias an der Heiden,

Christian Kollan,

Christian Hoffmann,

Jan van Lunzen,

Osamah Hamouda

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/599313

Subject(s) - viremia , medicine , cumulative incidence , lymphoma , hazard ratio , proportional hazards model , immunology , viral load , cohort , confidence interval , oncology , human immunodeficiency virus (hiv)

AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART). We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research